Ann: Swisswell Knee Patch Registered as a Medical Device, page-13

Congratulations to the company for TGA approval.

I am not convinced that this is not pseudoscience. I think that I am safe in saying this.

At 30 June 2022 they had 0.23 quarters of available funding. It is reasonable then to query this company as a going concern.

There appear to be a number of peers in the magnetic therapy for pain relief market. TGA approval may help but I would expect that they would need funds for marketing and funding is an obvious issue. They would need funding to continue trading before they could apply funds for growth.

They appear to have been trading quite some time considering the current level of revenue.

The TGA approval was enough reason to have a look at this stock. I could not invest in it though for the reasons given above.

But do your own research and form your own opinion before making your own investment decision.